Key Lessons & Opportunities in applying NCA and PopPK to ADCs
Applying NCA and PopPK to ADCs helps decode complex PK, balance DAR effects, and guide…
Certara2025 年 10 月 24 日
Highlights from the FDA Guidance on Dosage Optimization for Therapeutic Radiopharmaceuticals
Learn how radiopharmaceutical therapies work in oncology and how Certara supports development with modeling, simulation,…
Certara2025 年 10 月 3 日
What are the biggest roadblocks still standing in the way of cell and gene therapy commercialization?
Explore the top challenges in cell & gene therapy commercialization, featuring expert insights from Fran…
Certara2025 年 9 月 12 日
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
Certara2025 年 8 月 13 日
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial
Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…
Certara2025 年 8 月 13 日
Certara Announces D360 25.5 Release, Featuring Dynamic Data Subsets and Enhanced Analytics
D360 v25.5 allows scientists to divide up a dataset into series of compounds & perform…
Certara2025 年 8 月 7 日
Modeling Approaches for Determination of Pharmacokinetics/Pharmacodynamics
Explore insights from Certara experts on how PK/PD modeling streamlines biologic drug development.
Certara2025 年 8 月 5 日
FDA plans to phase out animal testing requirements
Discover how the FDA plans to replace animal testing with AI and organ-on-chip technologies for…
Certara2025 年 4 月 10 日
